A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.
Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA.
P R Health Sci J. 2005 Dec;24(4):269-76.
PMID: 16570523
Intravenously administered vitamin C as cancer therapy: three cases.\nPadayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M.\nCMAJ. 2006 Mar 28;174(7):937-42.\nPMID: 16567755 \ndoi:10.1503/cmaj.050346.
"Good research is good for medicine. The only thing more important than good research is ethical research. The February 16th issue of the New England Journal of Medicine (NEJM) had a research paper on vitamin D and colon cancer. Was it good research? Was it ethical research? At stake are the lives of 36,000 older American women who agreed to participate in the Women's Health Initiative. "
High prevalence of vitamin D inadequacy and implications for health.\nHolick MF.\nMayo Clin Proc. 2006 Mar;81(3):353-73. Review.\nPMID: 16529140 \ndoi: 10.4065/81.3.353\n
Not enough vitamin D: health consequences for Canadians.
Schwalfenberg G.
Can Fam Physician. 2007 May;53(5):841-54. Review
PMID: 17872747
Conclusion
Low levels of VTD are considered a major public health problem in Canada, especially during the winter. Those with risk factors should be screened for low 25(OH)D levels and repletion therapy instituted if needed. Researchers have estimated that the oral dose of vitamin D3 to attain and maintain 25(OH)D levels >80 nmol/L is 2200 IU/d if baseline levels are 20 to 40 nmol/L, 1800 IU/d if levels are 40 to 60 nmol/L, and 1160 IU/d if levels are between 60 and 80 nmol/L.64
We need to ensure that patients have healthy blood levels of 25(OH)D to prevent levels of parathyroid hormone from rising and to maximize absorption of calcium, magnesium, and phosphate. Positive effects on bone are marginal at best unless patients consume at least 800 IU/d of VTD. The emerging and exciting role of the VTD receptor and the actions of VTD in maintaining health in other cell types have become more apparent during the last decade.
Researchers are curious about curcumin to create an effective anti-infection therapeutic effect and control fungal infections in cancer patients. Curcumin could grow the fungal infection sustainability among cancer patients with candida.
Thus, turmeric curcumin supplements offer a reasonably 'secure cure' against candida with minimal or no adverse effects, even when using a higher curcumin dose.
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.\nRiordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, González MJ, Mora EM, Miranda-Massari JR, Rosario N, Rivera A.\nP R Health Sci J. 2004 Jun;23(2):115-8.\nPMID: 15377059
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo.\nChen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M.\nProc Natl Acad Sci U S A. 2007 May 22;104(21):8749-54. Epub 2007 May 14.\nPMID: 17502596 \n doi: 10.1073/pnas.0702854104\n